CHEMBIO DIAGNOSTICS, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2020-12-17: Form 8-K; Period of report 2020-12-17; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2020-12-04: Form 8-K; Period of report 2020-12-03; Description 8.01 Other Events; Details 8.01.
- 2020-11-05: Form 8-K; Period of report 2020-11-05; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2020-08-06: Form 8-K; Period of report 2020-08-06; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2020-12-17 | 8-K | 2020-12-17 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On December 17, 2020, the board of directors elected David W.K. Acheson as a member of the board, with a term effective on December 17, 2020 and continuing until our 2021 annual meeting of stockholders. | brhc10018060_8k.htm |
| 2020-12-04 | 8-K | 2020-12-03 | 8.01 Other Events | 8.01 On December 2, 2020, we issued a press release titled “Chembio Diagnostics Awarded $12.7 Million by BARDA for Development of Rapid DPP Respiratory Antigen Panel and 510(k) Submission of the Rapid DPP SARS-CoV-2 Antigen Test System.” A copy of the press release is included as Exhibit 99.1 to this report. | brhc10017606_8k.htm |
| 2020-11-05 | 8-K | 2020-11-05 | 2.02 Results of Operations and Financial Condition | 2.02 On November 5, 2020, we issued a press release announcing financial results for the quarter ended September 30, 2020. | brhc10016666.htm |
| 2020-08-06 | 8-K | 2020-08-06 | 2.02 Results of Operations and Financial Condition | 2.02 On August 6, 2020, we issued a press release announcing financial results for the quarter ended June 30, 2020. | brhc10014166_8-k.htm |
| 2020-08-04 | 8-K | 2020-07-28 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 We held our 2020 Annual Meeting of Stockholders on July 28, 2020. | brhc10014051_8k.htm |
| 2020-07-08 | 8-K | 2020-07-01 | 8.01 Other Events | 8.01 On July 1, 2020, the following purported class action lawsuit was filed by an alleged stockholder of ours in the United States District Court for the Eastern District of New York: Ken Hayes v. | form8k.htm |
| 2020-07-07 | 8-K | 2020-06-30 | 1.01 Entry into a Material Definitive Agreement; 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 2.02 On July 6, 2020, we issued a press release, which we refer to as the Release, announcing preliminary estimates of certain financial information for the quarter ended June 30, 2020. 7.01 On July 6, 2020, we issued press releases titled “Chembio Announces Plans to Seek EUA Approval from FDA for Revised DPP COVID-19 IgM/IgG System and New DPP COVID-19 Antigen System” and “Chembio Diagnostics Awarded BARDA Grant for Development of DPP COVID-19 Point-of-Care Antigen System.” Copies of those press releases are furnished as Exhibits 99.3 and 99.4, respectively, to this report. 8.01 We have received from Perceptive Credit Holdings II, LP, or Perceptive, a waiver of the minimum total revenue covenant contained in our Credit Agreement and Guaranty dated as of September 3, 2019, with Perceptive and the Guarantors named therein. | form8k.htm |
| 2020-06-17 | 8-K | 2020-06-16 | 8.01 Other Events | 8.01 On June 16, 2020, we received a letter from the U.S. Food and Drug Administration, or FDA, notifying us that the FDA was revoking the Emergency Use Authorization, or EUA, granted in April 2020 with respect to our DPP COVID-19 System, which consists of our serological test for COVID-19 and one of our Micro Reader analyzers. | form8k.htm |
| 2020-05-11 | 8-K/A | 2020-04-20 | 8.01 Other Events | 8.01 On April 21, 2020, we filed a Current Report on Form 8-K announcing that we, through our subsidiary Chembio Diagnostic Systems Inc., had entered into a loan agreement with HSBC Bank USA, National Association, which we refer to as the PPP Loan, pursuant to the Paycheck Protection Program of the Coronavirus Aid, Relief, and Economic Security Act. | form8ka.htm |
| 2020-05-11 | 8-K | 2020-05-07 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 Attached as Exhibit 5.1 to this Current Report on Form 8-K is the opinion of Ballard Spahr LLP, our Nevada corporate counsel, regarding the legality of the 2,619,593 shares of common stock issued and sold to the Underwriters on May 11, 2020 in connection with the public offering. | form8k.htm |
| 2020-05-04 | 8-K | 2020-05-04 | 7.01 Regulation FD Disclosure | 7.01 On May 4, 2020, we issued a press release entitled “Chembio Diagnostics Attains CE Marking for DPP COVID-19 System for IgG and IgM Antibodies.” A copy of the press release is furnished as Exhibit 99.1 to this report. | form8k.htm |
| 2020-05-04 | 8-K | 2020-05-04 | 2.02 Results of Operations and Financial Condition | 2.02 On May 4, 2020, we issued a press release announcing financial results for the quarter ended March 31, 2020. | form8k.htm |
| 2020-04-21 | 8-K | 2020-04-20 | 8.01 Other Events | 8.01 On April 20, 2020, we, through our subsidiary Chembio Diagnostic Systems Inc., entered into a loan agreement with HSBC Bank USA, National Association, which we refer to as the PPP Loan, pursuant to the Paycheck Protection Program of the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act. | form8k.htm |
| 2020-04-02 | 8-K | 2020-03-30 | 4.01 Changes in Registrant's Certifying Accountant | 4.01 On March 27, 2020, the Audit Committee of our Board of Directors completed a competitive selection process to determine our independent registered public accounting firm for the fiscal year ending December 31, 2020. | form8k.htm |
| 2020-03-20 | 8-K | 2020-03-16 | 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 5.02 We entered into an employment agreement, dated March 4, 2020 and effective as of March 16, 2020, with Richard L. Eberly with respect to terms of his employment as our Chief Executive Officer and President. 7.01 On March 20, 2020, we issued a press release entitled “Chembio Diagnostics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4).” A copy of the press release is furnished as Exhibit 99.1 to this report. 8.01 On March 12, 2020, we announced that we had entered into a worldwide strategic partnership with LumiraDx Limited, or LumiraDx, to develop point-of-care diagnostic tests for the detection of the COVID-19 virus and IgM and IgG antibodies on both our and LumraDx’s platforms. | form8k.htm |
| 2020-03-13 | 8-K | 2020-03-12 | 2.02 Results of Operations and Financial Condition | 2.02 On March 12, 2020, we issued a press release announcing financial results for the quarter and fiscal year ended December 31, 2019. | form8k.htm |
| 2020-03-03 | 8-K | 2020-03-03 | 8.01 Other Events | 8.01 On February 21, 2020, we received a “not approvable” letter from the U.S. Food and Drug Administration, or FDA, with respect to our pre-market approval, or PMA, submission on our DPP HIV-Syphilis multiplex test for commercial use in the United States. | form8k.htm |
| 2020-01-21 | 8-K | 2020-01-17 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 9, 2020, we announced we had appointed Gail S. Page to serve as our Interim Chief Executive Officer. | from8k.htm |
| 2020-01-09 | 8-K | 2020-01-03 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 5.02 On January 9, 2020, we announced that John J. Sperzel III had notified the board of directors of his resignation as our Chief Executive Officer and President and one of our directors. 7.01 On January 9, 2020, we issued a press release entitled “Chembio Diagnostics Announces CEO Transition.” A copy of the press release is furnished as Exhibit 99.1 to this report. | form8k.htm |